Additional Relevant Details REMARC achieved the primary endpoint of a statistically significant improvement in progression-free survival for patients receiving REVLIMID. The interim analysis of overall survival, a key secondary endpoint, showed no benefit in the REVLIMID arm. Based upon these interim results, Celgenedoes not currently plan to seek approval for this indication.